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INTRODUCTION 
 
Non-homologous end-joining (NHEJ) is a DNA repair 
pathway that recognizes, processes and ligates DNA 
double-stranded breaks (DSB) throughout the cell cycle. 
NHEJ is required for lymphocyte development; in 
particular, to repair DSBs induced by the recombination 
activating genes (RAG) 1 and 2 in developing B and T  
 
lymphocytes, and by activation-induced cytidine 
deaminase (AID) in mature B cells [1]. NHEJ is 
initiated when Ku70 and Ku80 (Ku) are recruited to the 
DSB sites. Ku, together with DNA-dependent protein 
kinase, catalytic subunit (DNA-PKcs), forms the DNA-
PK holoenzyme [2]. Subsequently, the nuclease Artemis 
is recruited to the DSB sites to process DNA hairpins 
and overhangs [3]. Finally, DNA ligase IV (LIG4), X-
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Non-homologous end-joining (NHEJ) is a DNA repair pathway required to detect, process, and ligate DNA 
double-stranded breaks (DSBs) throughout the cell cycle. The NHEJ pathway is necessary for V(D)J 
recombination in developing B and T lymphocytes. During NHEJ, Ku70 and Ku80 form a heterodimer that 
recognizes DSBs and promotes recruitment and function of downstream factors PAXX, MRI, DNA-PKcs, Artemis, 
XLF, XRCC4, and LIG4. Mutations in several known NHEJ genes result in severe combined immunodeficiency 
(SCID). Inactivation of Mri, Paxx or Xlf in mice results in normal or mild phenotype, while combined inactivation 
of Xlf/Mri, Xlf/Paxx, or Xlf/Dna-pkcs leads to late embryonic lethality. Here, we describe three new mouse 
models. We demonstrate that deletion of Trp53 rescues embryonic lethality in mice with combined deficiencies 
of Xlf and Mri. Furthermore, Xlf-/-Mri-/-Trp53+/- and Xlf-/-Paxx-/-Trp53+/- mice possess reduced body weight, 
severely reduced mature lymphocyte counts, and accumulation of progenitor B cells. We also report that 
combined inactivation of Mri/Paxx results in live-born mice with modest phenotype, and combined inactivation 
of Mri/Dna-pkcs results in embryonic lethality. Therefore, we conclude that XLF is functionally redundant with 
MRI and PAXX during lymphocyte development in vivo. Moreover, Mri genetically interacts with Dna-pkcs and 
Paxx. 
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ray repair cross-complementing protein 4 (XRCC4) and 
XRCC4-like factor (XLF) mediate DNA end ligation. 
The NHEJ complex is stabilized by a paralogue of 
XRCC4 and XLF (PAXX) and a modulator of retroviral 
infection (MRI/CYREN) [4, 5].  
 
Inactivation of Ku70, Ku80, Dna-pkcs or Artemis results 
in severe combined immunodeficiency (SCID) 
characterized by lack of mature B and T lymphocytes 
[2, 3, 6–8]. Deletion of both alleles of Xrcc4 [9] or Lig4 
[10] results in late embryonic lethality in mice, which 
correlates with increased apoptosis in the central 
nervous system (CNS). Inactivation of Xlf (Cernunnos) 
only results in modest immunodeficiency in mice [11–
13], while mice lacking Paxx [14–17] or Mri [5, 18] 
display no overt phenotype.  
 
The mild phenotype observed in mice lacking XLF 
could be explained by functional redundancy between 
XLF and multiple DNA repair factors, including Ataxia 
telangiectasia mutated (ATM), histone H2AX [19], 
Mediator of DNA Damage Checkpoint 1 (MDC1) [20, 
21], p53-binding protein 1 (53BP1) [17, 22], RAG2 
[23], DNA-PKcs [20, 24, 25], PAXX [4, 14, 15, 20, 26–
28] and MRI [5]. However, combined inactivation of 
Xlf and Paxx [4, 14, 15, 20], as well as Xlf and Mri [5], 
results in late embryonic lethality in mice, presenting a 
challenge to the study of B and T lymphocyte 
development in vivo. It has also been shown that both 
embryonic lethality and increased levels of CNS 
neuronal apoptosis in mice with deficiency in Lig4 [9, 
10, 29, 30], Xrcc4 [9, 31], Xlf and Paxx [20], or Xlf and 
Dna-pkcs [24, 25] is p53-dependent.  
 
In this study, we rescue synthetic lethality from Xlf and 
Mri by inactivating one or two alleles of Trp53. We also 












 mice possess a leaky SCID phenotype with 
severely reduced mature B and T lymphocyte counts in 
the spleen, low mature T cell counts in the thymus, and 
accumulated progenitor B cells in the bone marrow. 
Finally, we demonstrate that MRI is functionally 




Inactivation of Trp53 gene rescued embryonic 
lethality in mice lacking XLF and MRI 
 
Combined inactivation of Xlf and Mri has previously 
been shown to result in synthetic lethality in mice [5]. 
To generate XLF/MRI deficient mice with altered 
expression of Trp53, we intercrossed an Mri
-/-
 strain 




 [20] strain. Next, we selected 












 mice. With PCR 



















(Figure 1A) among the resulting offspring. Mice lacking 
both XLF and MRI possessed reduced weight (12 g on 
average, p<0.0001) when compared with gender- and 
age-matched WT (19 g), Xlf
-/-
 (19 g) and Mri
-/-
 (20 g) 












mice were viable up to 






 mice to further characterize the 
development of B and T lymphocytes in vivo.  
 








To determine the roles of XLF and MRI in lymphocyte 
development in vivo, we isolated the thymus, spleen, 













and WT controls. Combined 
deficiency for XLF and MRI resulted in a 3-fold 
reduction in thymus size (32 mg on average, p<0.0001) 
and a 9-fold reduction in thymocyte count (1.9x10
7
, 
p<0.0001) when compared to single deficient or WT 
controls (Figure 1D). Similarly, both average spleen 
weight (22 mg, p<0.0001) and splenocyte count 
(2.0x10
7







decreased approximately 4-5 fold when compared with 
WT and single deficient controls (Figure 1E). The 
reduced number of splenocytes in XLF/MRI double-
deficient mice could be explained by decreased 







mice (Figure 1F–1H and Supplementary 
Tables 1–4). Specifically, CD3+ T cells were reduced 6-
fold (p<0.0001), while CD19+ B cells were reduced 50-
fold (p<0.0001) when compared with single deficient 
and WT controls (Figure 1F–1H). Likewise, counts of 
CD4+ and CD8+ T cells in the spleen (Supplementary 
Tables 3 and 4), were all dramatically reduced when 
compared with single deficient and WT controls (about 
4-fold, p<0.0001; Figure 1F, 1H) as well as counts of 
CD4+, CD8+ and CD4+CD8+ T cells in the thymus 
(Figure 1F, 1I and Supplementary Tables 5–7). From 
these observations, we conclude that XLF and MRI are 
functionally redundant during B and T lymphocytes 
development in mice.  
 
Leaky SCID in mice lacking XLF and PAXX 
 
Combined inactivation of XLF and PAXX has been 
shown to result in embryonic lethality in mice [4, 14, 
15, 20]. To determine the impact of XLF and PAXX on 
B and T cell development in vivo, we rescued the 
synthetic lethality by inactivating one allele of Trp53, as 
described previously [20]. We did not detect any direct 
influence of altered Trp53 genotype on lymphocyte 













 mice possess 
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mice. (A) Number of thirty-day-old mice (P30) of indicated 
genotypes. *Expected distribution assuming lethality. (B) Comparison of body size, thymi and spleens of XLF/MRI-deficient and XLF-deficient 










 mice. (D, E) Number (×10
6











 mice. (F) Flow cytometric analysis of thymic and splenic T cell subsets and splenic B cells. (G, H, I) Number 
(×10
6
























 mice were used as an immunodeficient control. Comparisons between 































































, p<0.0001 (****).  
 
www.aging-us.com 23581 AGING 
30- to 40-fold reduced thymocyte count (4.0x10
6
, 











) mice. This is reflected in 
decreased levels of double-positive CD4+CD8+ cells, 
as well as decreased levels of single-positive CD4+ and 
CD8+ T cells (Figure 1, Supplementary Figure 1, and 
Supplementary Tables 5–7). Spleen development was 
dramatically affected in mice lacking XLF and PAXX 
compared to WT and single-deficient controls, due to 
the lack of B cells and decreased T cell count (Figure 1, 
Supplementary Figure 1, and Supplementary Tables 1–














mice had a 100- to 600-fold reduction in CD19+ B 
splenocyte count (0.7x10
6
, p<0.0001) and a 50- to 90-
fold reduction in CD3+ splenocyte count (to 0.5x10
6
) 
(Figure 1F–1H and Supplementary Figure 1). From 
these results, we concluded that XLF and PAXX are 
functionally redundant during the B and T lymphocyte 
development in vivo.  
 
Early B cell development is abrogated in mice 
lacking XLF and MRI, or XLF and PAXX 
 







mice suggest a 
blockage in B cell development in the bone marrow. To 
investigate this further, we isolated the bone marrow 
cells from femora of mice lacking XLF, MRI or both 
XLF/MRI, and analyzed the proportions of 
B220+CD43+IgM- progenitor B cells and B220+CD43-
IgM+ immature and mature B cells. We detected only 
background levels of B220+CD43-IgM+ B cells in bone 







2A, 2B and Supplementary Table 8). However, these 
mice exhibited a 2- to 3-fold higher proportion of pro-B 


















 mice also 
possess background levels of IgM+ B cells (p<0.0001; 
Figure 2A, 2B and Supplementary Table 8) while 
having 3- to 4-fold higher proportion of pro-B cells 





(p<0.0001; Figure 2A, 2C and Supplementary Table 9). 
Therefore, we conclude that B cell development is 



















 mice possess a modest phenotype 
 
Both PAXX and MRI are NHEJ factors that are 
functionally redundant with XLF in mice. Combined 
inactivation of Paxx and Xlf [4, 14, 15, 20], or Mri and  
















 mice. (A) Flow 
cytometric analysis of developing B cells. Upper left boxes mark B220+CD43+IgM- progenitor B cell populations, and lower right boxes mark 























 mice. Comparisons between groups were made using one-way ANOVA, 
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 and WT male littermates with their respective thymi and 




 and WT mice. (D, E) Class switching analyzes of in vitro 
activated naïve B cells of indicated genotypes. 
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as well as in abrogated V(D)J recombination in vAbl 
pre-B cells [4, 5, 14, 15, 27]. To determine if Paxx 
genetically interacts with Mri, we intercrossed mice that 












 mice are live-born, fertile, and are similar in size 
to WT littermates (17 g, p>0.9999) (Figure 3A and 3B). 




 mice have 





 mice underwent normal T cell development 










 mice had reduced CD19+ B cell counts (Figure 





controls (p<0.0025). Moreover, CD19+ B cell counts 






 mice (p>0.9270), 
suggesting that combined depletion of PAXX and MRI 
has modest phenotype similar to the one in XLF-
deficient mice. CSR to IgG1 was performed in order to 
determine if DNA repair-dependent immunoglobulin 
production is affected in mature B cells lacking PAXX 
and MRI [16, 18]. Paxx inactivation did not affect Ig 
switch to IgG1 in MRI-deficient B cells (Figure 3D and 
3E). The quantity of IgG1+ cells after CSR stimulation 






 naïve B 
cells (p>0.73). From this, we can conclude that there is 
a genetic interaction between Paxx and Mri in vivo, and 
it is only detected in B cells. 
 
Synthetic lethality between Mri and Dna-pkcs in mice 
 
Both MRI and DNA-PKcs are functionally redundant 
with XLF in mouse development [5, 24]. Combined 
inactivation of Paxx and Mri (this study), or Paxx and 
Dna-pkcs [20] genes results in live-born mice that are 
indistinguishable from single deficient controls. To 





mouse strains, then 























 mice (out of 6 expected). To 










 mice, extracted and genotyped the embryos 




 mice at 
E14.5 (63mg), which were about 40% lighter than Mri
-/-
 
littermates (108mg) (Figure 4C and 4D). A Chi-Square 
test (χ
2
) was performed to determine if the embryonic 





 parents. With DF=2 and 
χ
2
=1.8, the corresponding p-value lies within the range 
0.25<p<0.5. This affirms that our data fit the expected 





synthetic lethal. Therefore, we can conclude that there is 
genetic interaction between Mri and Dna-pkcs in vivo. 
DISCUSSION 
 
Recent findings by our and other research groups 
suggest that MRI forms heterogeneous complexes 
involving PAXX or XLF, which function during DNA 
DSB repair by NHEJ [5]. Furthermore, genetic 
inactivation of Xlf [11], Paxx [4, 14–16], or Mri [5, 18] 
in mice leads to development of modest or no detectable 
phenotype. However, combined inactivation of Xlf and 
Mri [5] or Xlf and Paxx [4, 14, 15] results in embryonic 
lethality, which correlates with increased levels of 
neuronal apoptosis in the CNS (Figure 5). Here, we 
show that synthetic lethality produced by combined 
inactivation of Xlf and Mri can be rescued by altered 






 [20] mouse model. Furthermore, we have 








 double deficient models. 
 
Our findings have demonstrated that mice lacking XLF, 







 mice have a clear fraction 
of mature B cells in the spleens (CD19+) and bone 
marrow (B220+CD43-IgM+) (Figures 1 and 2), as well 
as clear fractions of double- and single-positive T cells 
in the thymus (CD4+CD8+, CD4+, CD8+) and single-
positive T cells in the spleen (CD4+ and CD8+) (Figure 
1). However, the cell fractions from these mice are 
noticeably smaller than those of WT or single-deficient 













 mice of similar age with 
respect of B and T cell development (Supplementary 
Table 10), although this mouse was generally sicker 





 mouse was reported by 
Balmus et al. 2016 [15], indicating that, exceptionally, 
embryonic lethality in NHEJ ligation-deficient mice can 
be overcome, likely due to activity of alternative end-
joining. Previously, in 2018, Hung et al. [5] reported 
that combined inactivation of Xlf and Mri in vAbl pre-B 
cells results in a severe block in V(D)J recombination 
and accumulation of unrepaired DSBs in vitro, although 
it was unclear whether this combined inactivation 
would lead to a deficiency in B lymphocytes when 
translated to a mouse model [5]. Similarly, double 
deficient vAbl pre-B cells lacking Xlf and Paxx are also 
unable to sustain V(D)J recombination. Importantly, the 
lack of a progenitor T cell model system left the 








 mice completely unexplored. 
 
Previously, we showed that mice lacking XLF, PAXX 
and p53 were live-born and had nearly no B and T cells, 
reduced size of spleen and hardly detectable thymus [20] 
(Figure 5). Consistent with this model, a conditional 
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knockout mouse model, which results in double-
deficiency of XLF/PAXX in early hematopoietic 
progenitor cells, was also able to overcome the 




 mice [33]. With this 





cells, as well as the resulting depletion of mature B cells 
and lack of a visible thymus could also be observed in 












 mice possess a very 
small number of mature B cells in the spleen and bone 
marrow, as well as very minor fractions of single positive 
T cells in thymus and spleen (Figures 2, 5 and 
Supplementary Figure 1). Therefore, both mature B and 
T cells are present in mice lacking XLF/PAXX and 
XLF/MRI. This can be explained by incomplete blockage 
in NHEJ and V(D)J recombination, in which the process 
is dramatically reduced but still possible. We also 
detected more mature T cells than B cells in these 
double-deficient mice. Potential explanations include 
longer lifespan of T cells, which accumulate over time 
following low efficiency of V(D)J recombination, while 
B cells are eliminated faster from the pool due to the 
different physiology [34, 35]. It is also possible that the T 
cells we detected are a resultant subpopulation that is 
descendent from the few cells that were able to bypass 
V(D)J recombination [12]. In this case, the repertoire of 
T cells based on T cell receptor in mice lacking 
XLF/PAXX and XLF/MRI would be significantly lower 
than in control mice, even if normalized to the total cell 



















 mice, we categorize the observed immuno-
deficient phenotypes as “leaky SCID”. Previously, leaky 
SCID has been described in mice lacking other NHEJ 






















In addition to XLF/MRI and XLF/PAXX deficient 
mice, inactivation of one or two alleles of Trp53 also 
rescues the embryonic lethality of Xrcc4
-/-
 [9, 31],  
Lig4
-/-




[20] mice. We 
propose a model (Figure 5), when single deficiency for 




Figure 4. Genetic interaction between Mri and Dna-pkcs in vivo. (A) No live-born Mri-/-Dna-pkcs-/- mice were detected. (B, C) Mri-/-
Dna-pkcs
-/-












 was 1.8 and its 
corresponding probability was between 25 and 50%. *Expected distribution assuming lethality. 
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Figure 5. Mutations in NHEJ genes result in distinct phenotypes. Suggested models. Inactivation of Paxx or Mri results in live-born 
mice with nearly no DNA repair defects. Inactivation of Xlf or Dna-pkcs results in live-born mice with increased levels of genomic instability 
due to reduced NHEJ activity. Combined inactivation of Xlf/Paxx, Xlf/Mri or Xlf/Dna-pkcs leads to embryonic lethality in mice that correlate 
with high levels of genomic instability and nearly no NHEJ. Accumulated DSBs activate the ATM-dependent DNA damage response (DDR) 
pathway; ATM phosphorylates CHK checkpoint proteins that further trigger cell cycle arrest and apoptosis. Alternative end-joining is blocked 
by presence of Ku70/Ku80. Inactivation of one or two alleles of Trp53 rescues embryonic lethality of Xlf/Paxx, Xlf/Mri and Xlf/Dna-pkcs mice. 
While in these mice the levels of DSBs are increased and ATM-dependent DDR response is activated, lack of p53 prevents massive apoptosis 
and thus results in alive mice. Sizes of the triple-deficient mice are reduced, as one option, due to DNA damage-dependent cell cycle arrest in 
multiple cells of the body. The embryonic lethality in mice lacking Xlf/Paxx and Xlf/Mri is likely to be rescued by inactivation of Ku70 or Ku80.  
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phenotypes, and DSBs are efficiently repaired. 
Combined inactivation of Xlf/Dna-pkcs, Xlf/Paxx and 
Xlf/Mri results in inefficient DSB ligation, 
accumulation of DNA breaks, activation of ATM-
dependent DDR, checkpoint protein CHK2, 
stabilization of p53 and massive apoptosis. This results 
in embryonic lethality in mice. Furthermore, 
inactivation of Trp53 results in Xlf/Dna-pkcs/Trp53, 
Xlf/Paxx/Trp53 and Xlf/Mri/Trp53 triple-deficient 
mice. While DNA breaks in these mice are not 
repaired, ATM-dependent DDR response and 
activation of CHK proteins takes place. However, 
without p53, apoptosis is not activated, allowing 
survival of mice (Figure 5). Moreover, we propose that 
inactivation of Atm will also rescue embryonic lethality 
of Xlf/Paxx and Xlf/Mri mice due to the mechanisms 
proposed above. However, inactivation of Atm will not 
rescue embryonic lethality of Xlf/Dna-pkcs mice, due 
to synthetic lethality between Atm and Dna-pkcs.  
 
It is important to note that altered Trp53 expression is 
not always sufficient to rescue embryonic lethality in 
mice; for example, PLK1-interacting checkpoint 
helicase (PICH)-deficient mice possess developmental 
defects in the presence or absence of p53 [36], and ATR 
mutants (Seckel syndrome) are not completely rescued 
from embryonic lethality with the inactivation of Trp53 
[37]. Embryonic lethality of XLF/PAXX and XLF/MRI 
double-deficient mice can be explained by the presence 
of Ku70/Ku80 heterodimer at the DSBs sites, which 
blocks DNA repair by alternative end-joining 
pathway(s), leading to massive apoptosis and cell cycle 
arrest [38]. Previously, it was shown that embryonic 
lethality of LIG4-deficient [39] and XLF/DNA-PKcs 
double-deficient mice [25] could be rescued by 
inactivating Ku70 or Ku80 genes. Similarly, we propose 
that inactivation of either Ku70 or Ku80 gene will 
rescue the embryonic lethality of XLF/PAXX and 
XLF/MRI double-deficient mice and will result in mice 
indistinguishable from Ku70- or Ku80-deficient 
controls (Figure 5). 
 
Recent studies have shown that Xlf genetically interacts 
with Rag2 [23] and DDR factors, such as Atm, 53bp1, 





almost completely lack mature B cells and have 









 mice are live-
born and exhibit reduced body weight, increased 
genomic instability, and severe lymphocytopenia as a 
result of V(D)J recombination impairment in 









, on the other hand, are embryonic lethal 
[19–21]. There are several possible explanations for the 
functional redundancy observed between DNA repair 
genes. For instance, the two factors could have identical 
(e.g., if both proteins are involved in ligation or DNA 
end tethering) or complementary (e.g., if one protein 
stimulates ligation while the other is required for DNA 
end tethering) functions. To date, XLF has been shown 
to genetically interact with multiple DNA repair factors 
[1, 4, 5, 14, 15, 19, 20, 24, 25], and this list is likely to 
grow [38, 40]. However, no clear genetic interaction has 
been shown between Xlf and Artemis or Xrcc4 in the 
context of mouse development and V(D)J re-
combination [24], meaning that it remains difficult to 
predict genetic interactions without developing and 
characterizing genetic models. 
 





) are live-born, fertile, and undergo 
almost normal B and T cell development (Figure 3), 
where only the number of splenic B cells is affected, 
giving rise to a modest phenotype. Moreover, 
inactivation of Paxx did not affect the CSR efficiency in 
in vitro stimulated MRI-deficient B cells (Figure 3), 
thereby confirming our observations in vitro. It has been 
also shown that combined inactivation of Paxx and Mri 
genes in vAbl pre-B cells lead to similar V(D)J 





and WT controls [5]. Thus, we conclude that there is a 
genetic interaction between Paxx and Mri, which results 
in a modest phenotype. 
 





) leads to embryonic 





embryos were about 40% smaller than single-deficient 
siblings (Figure 4). DNA-PKcs is associated with the N-
terminus of the MRI and Ku heterodimer in the process 
of recognizing DSBs [5], which may account for 
genetic interaction between Mri and Dna-pkcs. Thus, 
inactivation of Trp53, Ku70 or Ku80 may be a viable 







In conclusion, we have developed and described several 












 mice possessed 










 mice are embryonic 
lethal.  
 




All experiments involving mice were performed 
according to the protocols approved by the Comparative 
Medicine Core Facility (CoMed) at the Norwegian 
University of Science and Technology (NTNU, 
 
www.aging-us.com 23587 AGING 
Trondheim, Norway). Xlf
+/-
 [11] and Dna-pkcs
+/-
 [2] 
mice were imported from the laboratory of Professor 
Frederick W. Alt at Harvard Medical School. Trp53
+/-
 





 [18] mice were generated by the 




Lymphocyte populations were analyzed by flow 
cytometry [16, 18, 19, 22]. In summary, cells were 
isolated from the spleen, thymus, and femur of 5-7-
week-old mice and treated with red blood cell lysis 
buffer Hybri-Max
TM
 (Sigma Aldrich, St. Louis, MO, 
USA; #R7757). The cells were resuspended in PBS 
(Thermo Scientific, Basingstoke, UK; #BR0014G) 
containing 5% Fetal bovine serum, FCS (Sigma Life 
Science, St. Louis, Missouri, United States; #F7524), 
and counted using a Countess™ II Automated Cell 
Counter (Invitrogen, Carlsbad, CA, United States; 
#A27977). Then, the cell suspension was diluted with 
PBS to get a final cell concentration of 2.5 x 10
7 
cells/mL. Finally, surface markers were labeled with 
fluorochrome-conjugated antibodies and the cell 
populations were analyzed using flow cytometry. 
 
Class switch recombination (CSR) 
 
Spleens were isolated from 5-7-week-old mice and stored 
in cold PBS. Splenocytes were obtained by mincing the 
spleens, and naïve B cells were negatively selected using 
an EasySep Isolation kit (Stemcell™, Cambridge, UK; 
#19854). Lipopolysaccharide (LPS; 40 μg/mL; Sigma 
Aldrich, St. Louis, MO, USA; #437627-5MG) and 
interleukin 4 (IL-4; 20 ng/mL; PeproTech, Stockholm, 
Sweden; #214-14) were used to induce CSR to IgG1. 




The following antibodies were used for flow cytometric 
analysis: rat anti-CD4-PE-Cy7 (BD Pharmingen
TM
, 
Allschwil, Switzerland, #552775; 1:100); rat anti-CD8-
PE-Cy5 (BD Pharmingen
TM
, Allschwil, Switzerland, 
#553034; 1:100); anti-CD19-PE-Cy7 (Biolegend, San 












Switzerland; #553092; 1:100); rat anti-mouse anti-IgM-
PE-Cy7 (BD Pharmingen
TM
, Allschwil, Switzerland, 
#552867; 1:100); rat anti-mouse IgG1-APC (BD 
Pharmingen
TM
, Allschwil, Switzerland; #550874; 
1:100). A LIVE/DEAD™ fixable violet dead cell stain 
kit (ThermoFisher Scientific, Waltham, MA, USA; 




Statistical analyses were performed using one-way 
ANOVA, GraphPad Prism 8.0.1.244 (San Diego, CA, 
USA). In all statistical tests, p<0.05 were taken to  
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2.70 2.39 3.48 0.64 4.34 0.18 0.19 1.08 0.02 
2.00 1.83 3.43 0.33 2.93 0.06 0.09 1.85 0.001 
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Supplementary Table 7. Summary of thymic CD4+CD8+ double positive T cells. 
 
































154.05 48.40 160.60 20.69 132.56 2.68 6.22 75.37 0.17 
141.52 73.77 133.62 11.40 161.22 7.21 6.54 184.27 0.002 
230.74 163.07 14.22 21.18 151.30 6.79 5.14 122.11 0.0002 
147.74 95.47 165.78 17.78 208.39 3.39  105.44 0.001 
138.62 115.71 154.74 17.71 202.99 3.72  88.37 0.002 
98.78 115.77 193.15 
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19.80 7.82 17.10 3.04 17.8 2.19 3.26 15.90 
16.70 11.00 16.30 1.47 14.3 2.53 4.01 16.70 
18.60 8.47 16.00 1.42 15.9 4.09 3.55 14.30 
10.10 6.04 15.80 1.10 11.9 0.37  14.00 
14.10 7.68 13.80 1.57 
 
4.60  10.10 
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6.00 21.6 3.74 24.90 8.92 33.70 20.10 7.53 
7.47 8.73 4.31 14.50 4.40 28.40 24.00 7.04 
3.38 17.5 9.53 17.20 4.07 23.20 25.60 8.64 
6.96 10.9 7.03 14.90 3.81 21.90  10.9 
5.02 9.61 6.73 19.00  26.80  9.00 
5.49 7.99 6.58   27.10  6.28 
2.75 5.31 4.17   25.10  6.76 
4.25 7.16 4.28   17.30  6.20 
7.58 6.08    22.20  3.32 
7.47     25.50  4.06 
5.03        
7.72        
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Cell populations (%) in 
bone marrow 
CD19+ B cells CD3+ T cells CD4+ T cells CD8+ T cells CD4+ T cells CD8+ T cells CD4+CD8+ T cells IgM+ B cells Pro-B cells 
0.11 0.80 0.53 0.41 0.42 0.41 15.70 2.71 19.40 
Summary of splenic (×10
6
) B- and T cells; and T cell subpopulations in the thymus (×10
6
). Frequencies (%) in bone marrow of 
B220+CD43-IgM+ B cells and B220+CD43+IgM- pro-B cells. 
